Rucaparib
Synonym
Product Category
Product Code
CAS Number
MDL Number
Pubchem CID
Reaxys RN
Rucaparib free base, AG-014447
API & Intermediates
KAPI1F13
283173-50-2
MFCD11977252
9931954
11556434

Chemical Name
Molecular Formula
Molecular Weight
Assay
Appearance
Melting Point
Packaging
Storage
Rucaparib
C19H18FN3O
323.37
≥99%(HPLC)
White Solid
220°C
500mg,1g,10g,25g,50g,100g and 500g
-20°C Freezer
Rucaparib (also known as Rucaparib free base, AG-014447 ) is a Poly(ADP-ribose) polymerases (PARPs) inhibitor used as an anti-cancer agent.
Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. [1]
Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. [2]
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. [3]
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. [4]
Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer? [5]
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. [6]
Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2 . [7]
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. [8]
Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer. [9]
Poly(ADP-Ribose) Polymerase Inhibitor PJ34 Attenuated Hepatic Triglyceride Accumulation in Alcoholic Fatty Liver Disease in Mice. [10]
References:
[1] B.P.Rowe, et al, Breast Cancer Res., 2010, 12(2), pp 1-11.
[2] R.A.Daniel, et al, Br. J. Cancer, 2010, 103(10), pp 1588-1596.
[3] Y.Yuan, et al, J. Hematol. Oncol., 2011, 4(16), pp 1-14.
[4] M. Javle, et al, Ther. Adv. Med. Oncol., 2011, 3(6), pp 257-267.
[5] R.Plummer, et al, Breast cancer Res., 2011, 13(4), pp 1-6.
[6] N.Johnson, et al, Nature Medicine, 2011, 17(7),pp 875-882.
[7] Y.Drew, et al, J. Natl. Cancer Inst., 2011, 103(4), pp 334-346.
[8] Y.Drew, et al, Br. J. Cancer., 2016, 114(7), pp 723-730.
[9] M.Zanjirband, et al, Oncotarget, 2017, 8(41), pp 69779-69796.
[10] S.Huang, et al, J. Pharmacol. Exp. Ther., 2018, 364(3), pp 452-461.
Signal Word
Hazard Statements
Precautionary Statements
HS Code
RIDADR
Legal Information
Not classified as a dangerous goods
NONH for all modes of transport
Sales restrictions may apply.
Please inquire for pricing and availability of this product by writing email to sales@kumidas.com.